EcoDrugPlus

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSPREG00000018601
Gene Symbol: LOC103457804
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Alpha Type-7

Ensembl ID : ENSPREG00000004611
Gene Symbol: LOC103479568
3 Cross references
182 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSPREG00000022073
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSPREG00000018276
Gene Symbol: LOC103463873
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5

Ensembl ID : ENSPREG00000022102
Gene Symbol: LOC103478894
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSPREG00000008526
Gene Symbol: LOC103460825
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSPREG00000012274
Gene Symbol: LOC103473123
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSPREG00000004512
Gene Symbol: LOC103472925
3 Cross references
206 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSPREG00000011691
Gene Symbol: LOC103460926
3 Cross references
212 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSPREG00000004577
Gene Symbol: LOC103472928
3 Cross references
197 Possible Orthologues:

Proteasome Subunit Beta Type-9-Like

Ensembl ID : ENSPREG00000011650
Gene Symbol: LOC103460923
3 Cross references
201 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSPREG00000022051
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).